As one of the most prevalent forms of chronic liver disease worldwide, affecting more than one-fourth of the global population (1–3), NAFLD is characterized by hepatic steatosis in the absence of secondary factors contributing to a fatty liver, such as prolonged use of specific drugs (e.g., methotrexate and tamoxifen), excessive alcohol consumption, or genetic abnormalities (e.g., PNPLA3 and TM6SF2 polymorphisms) (4–8). This evidence concerns the gene PNPLA3 and fatty liver disease.